Search research articles
Contact Us
Filters
Showing results (21-30 of 60) with videos related to
Page
of 6
Sort By:
United European Gastroenterology Journal
|
August 18, 2025
Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy
Alica K Beutel, Christopher J Halbrook, Menar Ekizce, et al.
Zeitschrift Fur Gerontologie Und Geriatrie
|
July 14, 2021
[COVID-19 pandemic-related burden and SARS-CoV-2 prevalence in care facilities]
Lukas Perkhofer, Peter Grünke, Edonjeta Gashi-Ymeri, et al.
Cells
|
September 19, 2020
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Elodie Roger, Johann Gout, Frank Arnold, et al.
Cancers
|
October 23, 2021
<i>CDKN2A</i>-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome
Jessica Merkle, Markus Breunig, Maximilian Schmid, et al.
United European Gastroenterology Journal
|
March 8, 2018
Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study
Andreas W Berger, Katja Raedler, Cord Langner, et al.
BMC Cancer
|
January 17, 2016
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
Thomas J Ettrich, Lukas Perkhofer, Goetz von Wichert, et al.
International Journal of Cancer
|
September 15, 2020
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111)
Thomas J Ettrich, Lukas Perkhofer, Thomas Decker, et al.
Cancers
|
September 10, 2021
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
Lukas Perkhofer, Talia Golan, Pieter-Jan Cuyle, et al.
BMC Cancer
|
December 31, 2018
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
Thomas J Ettrich, Andreas W Berger, Lukas Perkhofer, et al.
Cancers
|
June 2, 2021
A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response
Alica K Beutel, Lena Schütte, Jeanette Scheible, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 60) with videos related to
Sort By:
Page
of 6
United European Gastroenterology Journal
|
August 18, 2025
Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy
Alica K Beutel, Christopher J Halbrook, Menar Ekizce, et al.
Zeitschrift Fur Gerontologie Und Geriatrie
|
July 14, 2021
[COVID-19 pandemic-related burden and SARS-CoV-2 prevalence in care facilities]
Lukas Perkhofer, Peter Grünke, Edonjeta Gashi-Ymeri, et al.
Cells
|
September 19, 2020
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Elodie Roger, Johann Gout, Frank Arnold, et al.
Cancers
|
October 23, 2021
<i>CDKN2A</i>-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome
Jessica Merkle, Markus Breunig, Maximilian Schmid, et al.
United European Gastroenterology Journal
|
March 8, 2018
Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study
Andreas W Berger, Katja Raedler, Cord Langner, et al.
BMC Cancer
|
January 17, 2016
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
Thomas J Ettrich, Lukas Perkhofer, Goetz von Wichert, et al.
International Journal of Cancer
|
September 15, 2020
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111)
Thomas J Ettrich, Lukas Perkhofer, Thomas Decker, et al.
Cancers
|
September 10, 2021
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
Lukas Perkhofer, Talia Golan, Pieter-Jan Cuyle, et al.
BMC Cancer
|
December 31, 2018
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
Thomas J Ettrich, Andreas W Berger, Lukas Perkhofer, et al.
Cancers
|
June 2, 2021
A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response
Alica K Beutel, Lena Schütte, Jeanette Scheible, et al.
Page
of 6